TY - JOUR
T1 - Extramedullary disease in Waldenström macroglobulinemia
T2 - A population‐based observational study
AU - Østergaard, Simon
AU - Munksgaard, Lars
AU - Nielsen, Torsten Holm
AU - Hammer, Troels
AU - Pedersen, Lars Møller
AU - Pedersen, Mette Ølgod
AU - Gjerdrum, Lise Mette Rahbek
PY - 2024
Y1 - 2024
N2 - Introduction: Extramedullary disease (EMD) is a rare manifestation of Waldenström macroglobulinemia (WM), and its clinical and prognostic implications are poorly understood. Methods: In this single-center study, we investigated the clinical significance of EMD in a cohort of 469 WM patients. Results: EMD was identified in 30 (6.4%) patients, with the central nervous system, kidneys, and lungs being the most frequently affected sites. The cumulative incidence of EMD was 12.6% at 15 years. Median overall survival rates at 5 and 10 years for patients with EMD were 63% and 37%, respectively. Conclusion: Our findings indicate a persistent risk of EMD throughout the disease course, with no significant impact on long-term survival.
AB - Introduction: Extramedullary disease (EMD) is a rare manifestation of Waldenström macroglobulinemia (WM), and its clinical and prognostic implications are poorly understood. Methods: In this single-center study, we investigated the clinical significance of EMD in a cohort of 469 WM patients. Results: EMD was identified in 30 (6.4%) patients, with the central nervous system, kidneys, and lungs being the most frequently affected sites. The cumulative incidence of EMD was 12.6% at 15 years. Median overall survival rates at 5 and 10 years for patients with EMD were 63% and 37%, respectively. Conclusion: Our findings indicate a persistent risk of EMD throughout the disease course, with no significant impact on long-term survival.
U2 - 10.1002/jha2.1037
DO - 10.1002/jha2.1037
M3 - Journal article
C2 - 39691270
SN - 2688-6146
VL - 5
SP - 1269
EP - 1273
JO - eJHaem
JF - eJHaem
IS - 6
ER -